top of page
E.nigma_Systemic_Delivery_blood_cells_--ar_43_600cf328-5452-4c2e-8917-fffd5ba62941_0.png

Systemic Delivery

Systemic delivery is crucial in preclinical drug development as it ensures that the investigational drug product reaches all relevant tissues and organs, mimicking the intended therapeutic distribution in humans. This comprehensive exposure allows for the assessment of the drug's pharmacokinetics, efficacy, and potential toxicity across the entire organism. By delivering the drug systemically, researchers can better predict the drug's behavior in human clinical trials, thereby enhancing the translational relevance of the preclinical findings and informing dose selection and safety margins.

​

NeuroPhys Solutions specializes in all methods of systemic delivery. We tailor our services to your needs and specifications. We can perform any of the delivery methods listed below.

  • Intraparenchymal (IPa)
    Intraparenchymal delivery is a route of administration that involves delivering a substance directly into the brain parenchyma. This method can help achieve high drug concentrations at the target site and avoid the blood-brain barrier (BBB).
  • Intra Cerebroventricular (ICV)
    Intracerebroventricular (ICV) injections are used to introduce compounds, drugs, and other agents into the central nervous system (CNS) of rodents. ICV injections can bypass the blood-brain barrier (BBB) and allow high concentrations of drugs to reach the brain's central compartment.
  • Intra Cisterna Magna (ICM)
    Intra cisterna magna (ICM) delivery is a method of injecting a therapeutics into the cerebrospinal fluid (CSF)-filled subarachnoid space between the cerebellum and the dorsal side of the medulla oblongata. ICM is less invasive than ICV, allowing for delivery directly to the spinal canal or subarachnoid space without interference with any CNS tissue, making its repeated delivery possible.
  • IntraThecal (IT)
    Intrathecal delivery involves the administration of drugs directly into the cerebrospinal fluid (CSF) within the spinal canal. This method bypasses the blood-brain barrier, allowing for targeted delivery of therapeutic agents to the central nervous system (CNS). By administering drugs intrathecally, researchers can achieve higher local concentrations of the drug in the CNS, enhancing therapeutic efficacy and reducing systemic side effects.
  • Acute/Chronic Infusions - Cannula Implantation, Osmotic Pumps
    Acute Infusions: These involve a single or short-term administration of a drug or other substance. This method is typically used to study immediate effects, such as drug pharmacodynamics, acute toxicity, or rapid therapeutic responses. Acute infusions are often delivered via specialized cannula implants into the target region. Chronic Infusions: In contrast, chronic infusions involve long-term administration, which can span days, weeks, or even months. This approach is used to study the effects of prolonged exposure to a substance, such as in the evaluation of potential treatments for chronic neurological diseases, long-term toxicity, and the progression of neurodegenerative conditions. Chronic infusions are typically administered through implanted devices, like osmotic minipumps, that provide a continuous and controlled release of the substance into the CNS.
  • Convection enhanced delivery (CED)
    Convection-enhanced delivery is a method for delivering therapeutic agents to large areas of the brain using bulk flow to increase hydrostatic pressure and improve volume distribution
bottom of page